Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias
- 25 November 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (22), 4591-4599
- https://doi.org/10.1182/blood-2009-10-247239
Abstract
The aberrant overexpression of Wilms tumor 1 (WT1) in myeloid leukemia plays an important role in blast cell survival and resistance to chemotherapy. High expression of WT1 is also associated with relapse and shortened disease-free survival in patients. However, the mechanisms by which WT1 expression is regulated in leukemia remain unclear. Here, we report that heat shock protein 90 (Hsp90), which plays a critical role in the folding and maturation of several oncogenic proteins, associates with WT1 protein and stabilizes its expression. Pharmacologic inhibition of Hsp90 resulted in ubiquitination and subsequent proteasome-dependant degradation of WT1. RNAi-mediated silencing of WT1 reduced the survival of leukemia cells and increased the sensitivity of these cells to chemotherapy and Hsp90 inhibition. Furthermore, Hsp90 inhibitors 17-AAG [17-(allylamino)-17-demethoxygeldanamycin] and STA-9090 significantly reduced the growth of myeloid leukemia xenografts in vivo and effectively down-regulated the expression of WT1 and its downstream target proteins, c-Myc and Bcl-2. Collectively, our studies identify WT1 as a novel Hsp90 client and support the crucial role for the WT1–Hsp90 interaction in maintaining leukemia cell survival. These findings have significant implications for developing effective therapies for myeloid leukemias and offer a strategy to inhibit the oncogenic func-tions of WT1 by clinically available Hsp90 inhibitors.Keywords
This publication has 52 references indexed in Scilit:
- TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levelsNucleic Acids Research, 2008
- The post-transcriptional roles of WT1, a multifunctional zinc-finger proteinBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell linesLeukemia, 2007
- Rearrangements of the Williams–Beuren syndrome locus: molecular basis and implications for speech and language developmentExpert Reviews in Molecular Medicine, 2007
- The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesisExpert Reviews in Molecular Medicine, 2007
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced CancerClinical Cancer Research, 2007
- A tumor suppressor and oncogene: the WT1 storyLeukemia, 2007
- High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid LeukemiaJournal of Clinical Oncology, 2006
- WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients – results from a single‐centre studyBritish Journal of Haematology, 2004
- A Non-AUG Translational Initiation Event Generates Novel WT1 IsoformsPublished by Elsevier BV ,1996